Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-008942.pdf
0001179110-21-008942.rtf
0001179110-21-008942.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-008943.pdf
0001179110-21-008943.rtf
0001179110-21-008943.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-008944.pdf
0001179110-21-008944.rtf
0001179110-21-008944.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-008826.pdf
0001179110-21-008826.rtf
0001179110-21-008826.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-008827.pdf
0001179110-21-008827.rtf
0001179110-21-008827.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-008782.pdf
0001179110-21-008782.rtf
0001179110-21-008782.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-008783.pdf
0001179110-21-008783.rtf
0001179110-21-008783.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-008474.pdf
0001179110-21-008474.rtf
0001179110-21-008474.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-008347.pdf
0001179110-21-008347.rtf
0001179110-21-008347.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-008304.pdf
0001179110-21-008304.rtf
0001179110-21-008304.xls